title: Depletion of regulatory T cells by targeting CC chemokine receptor type 4 with mogamulizumab.
abstract: The CC chemokine receptor 4 (CCR4) is highly expressed on type 2 helper T cells and regulatory T (Treg) cells. Mogamulizumab, an anti-CCR4 antibody, reduces the numbers of CCR4+malignant T cells and CCR4+Treg cells in cutaneous T-cell lymphoma. Depleting Treg cells by targeting CCR4 has great potential in cancer immunotherapies.
authors.affiliation: Department of Dermatology; The University of Texas MD Anderson Cancer Center ; Houston, TX USA.
authors.forename: Xiao
authors.initials: X
authors.lastname: Ni
authors.affiliation: Department of Dermatology; The University of Texas MD Anderson Cancer Center ; Houston, TX USA.
authors.forename: Timothy
authors.initials: T
authors.lastname: Langridge
authors.affiliation: Department of Dermatology; The University of Texas MD Anderson Cancer Center ; Houston, TX USA.
authors.forename: Madeleine
authors.initials: M
authors.lastname: Duvic
keywords: Sézary syndrome; chemokine receptor; cutaneous T-cell lymphoma; mogamulizumab; monoclonal antibody; mycosis fungoides; regulatory T cells; targeted therapy